FDA Expands ERVEBO Approval to Children Aged 12 Months and Older (merck.com)

• FDA approved ERVEBO for children 12 months and older.
• Data showed strong immune response and safety in children.
• Expansion supports pediatric vaccination in Ebola outbreaks.

"The U.S. FDA approved an expanded indication for Merck's Ebola vaccine ERVEBO to include children 12 months and older. The decision is based on clinical data showing immune responses and safety in pediatric populations. This regulatory action enhances pediatric vaccination capabilities in outbreak settings."